Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published 11 April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer

Huang H, Feng H, Qiao H, Ren Z, Zhu G

OncoTargets and Therapy 2015, 8:1157-1164

Published Date: 22 May 2015

Surgical therapy versus observation for lamellar macular hole: a retrospective comparison study

Sanisoglu H, Elbay A, Sevim S, Celik U, Aktas FB, Durmus E

Clinical Ophthalmology 2013, 7:1843-1848

Published Date: 18 September 2013

A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma

Garcia-Feijoo J, Sampaolesi JR

Clinical Ophthalmology 2012, 6:441-446

Published Date: 22 March 2012

Gemcitabine and taxanes in metastatic breast cancer: a systematic review

Vinay Gudena, Alberto J Montero, Stefan Glück

Therapeutics and Clinical Risk Management 2008, 4:1157-1164

Published Date: 5 December 2008

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Walter Deberdt, Ilya Lipkovich, Alexandra N Heinloth, Lin Liu, Sara Kollack-Walker, et al

Therapeutics and Clinical Risk Management 2008, 4:713-720

Published Date: 8 August 2008

New approaches to managing asthma: a US perspective

William E Berger

Therapeutics and Clinical Risk Management 2008, 4:363-379

Published Date: 11 April 2008

Managing anemia in lymphoma and multiple myeloma

Gunnar Birgegård

Therapeutics and Clinical Risk Management 2008, 4:527-539

Published Date: 11 April 2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Therapeutics and Clinical Risk Management 2008, 4:163-187

Published Date: 8 February 2008